Opaleye Management’s PDS Biotechnology PDSB Stock Holding History

Opaleye Management’s Portfolio PDSB Stock Details PDSB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-6,500	Closed	-$1.33M	–	36
2017 Q2	$1.33M	Sell	6,500 -7,500	-54%	-$1.48M	0.56%	35
2017 Q1	$2.55M	Hold	14,000	–	–	1.27%	25
2016 Q4	$3.5M	Hold	14,000	–	–	2.06%	18
2016 Q3	$2.92M	Buy	14,000 +2,720	+24%	+$539K	1.53%	24
2016 Q2	$2.28M	Buy	11,280 +2,030	+22%	+$359K	1.52%	25
2016 Q1	$1.69M	Buy	+9,250	New	+$1.65M	1.06%	34

Other funds holding PDSB

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Opaleye Management's PDSB Position: Q3 2017 in Review

Opaleye Management sold out of PDS Biotechnology (PDSB) in Q3 2017, closing a stake of 6,500 shares — an estimated $1.33M sold.

Opaleye Management first reported a position in PDSB in Q1 2016 and held it in 6 quarters. The position peaked at $3.5M in Q4 2016. 55 funds tracked by Wall St. Rank hold PDSB as of Q3 2017.

Opaleye Management reported no remaining PDS Biotechnology position as of Q3 2017 after selling out during the quarter.
Opaleye Management sold 6,500 PDS Biotechnology shares in Q3 2017, an estimated $1.33M.
Opaleye Management first reported a position in PDS Biotechnology in Q1 2016 and held it in 6 quarters.
Opaleye Management's PDS Biotechnology position peaked at $3.5M in Q4 2016.
55 funds tracked by Wall St. Rank held PDS Biotechnology as of Q3 2017.

Based on Opaleye Management's 13F filing for Q3 2017, filed 14 Nov 2017.